NASDAQ:TTPH - Tetraphase Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
+0.30 (1.20%)
Get New Tetraphase Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TTPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TTPH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Tetraphase Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.20.

This chart shows the closing price for TTPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Tetraphase Pharmaceuticals. This rating has held steady since June 2021, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/26/2020G.ResearchDowngradeHold ➝ SellLow
5/7/2020G.ResearchUpgradeSell ➝ HoldLow
5/7/2020GabelliUpgradeSell ➝ HoldHigh
3/17/2020G.ResearchDowngradeHold ➝ SellHigh
3/16/2020GabelliDowngradeHold ➝ SellHigh
1/24/2020G.ResearchDowngradeBuy ➝ HoldMedium
1/24/2020GabelliDowngradeBuy ➝ HoldMedium
11/13/2019HC WainwrightReiterated RatingHoldHigh
11/5/2019HC WainwrightReiterated RatingHoldLow
10/31/2019G.ResearchUpgradeHold ➝ BuyMedium
10/31/2019GabelliUpgradeHold ➝ BuyHigh
9/3/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
8/11/2019Needham & Company LLCReiterated RatingHoldHigh
8/11/2019HC WainwrightReiterated RatingBuy$40.00High
5/12/2019Needham & Company LLCReiterated RatingHoldHigh
5/10/2019SunTrust BanksLower Price TargetBuy$80.00High
5/6/2019HC WainwrightReiterated RatingBuy$140.00High
3/15/2019GabelliDowngradeBuy ➝ Hold$28.00High
3/15/2019Piper Jaffray CompaniesLower Price TargetOverweight$120.00 ➝ $80.00High
1/7/2019Robert W. BairdReiterated RatingBuy$60.00High
1/4/2019B. RileyInitiated CoverageBuy$60.00Low
10/11/2018Piper Jaffray CompaniesLower Price TargetOverweight$120.00High
9/6/2018WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$140.00High
8/28/2018B. RileyBoost Price TargetBuy ➝ Buy$120.00 ➝ $140.00High
8/28/2018HC WainwrightBoost Price TargetBuy ➝ Buy$120.00 ➝ $140.00High
8/3/2018Needham & Company LLCReiterated RatingHoldLow
7/16/2018HC WainwrightReiterated RatingBuyLow
5/4/2018HC WainwrightReiterated RatingBuy$120.00High
3/29/2018GabelliUpgradeHold ➝ BuyLow
3/8/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$55.00 ➝ $60.00High
3/7/2018Needham & Company LLCReiterated RatingHoldHigh
2/22/2018WBB SecuritiesInitiated CoverageSpeculative Buy ➝ Speculative Buy$120.00Medium
2/14/2018SunTrust BanksReiterated RatingBuy$200.00Medium
2/14/2018Stifel NicolausLower Price TargetBuy ➝ Buy$260.00 ➝ $120.00N/A
2/14/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$480.00N/A
2/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$160.00N/A
2/14/2018HC WainwrightLower Price TargetBuy ➝ Buy$340.00 ➝ $120.00N/A
2/12/2018B. RileyInitiated CoverageBuy ➝ Buy$220.00High
2/6/2018HC WainwrightReiterated RatingBuy$340.00High
12/5/2017HC WainwrightReiterated RatingBuy$340.00Low
11/6/2017HC WainwrightBoost Price TargetBuy$300.00 ➝ $340.00N/A
10/4/2017BMO Capital MarketsBoost Price TargetOutperform$260.00 ➝ $480.00N/A
9/17/2017Needham & Company LLCReiterated RatingHoldHigh
9/12/2017Stifel NicolausReiterated RatingBuy$260.00Low
8/28/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$280.00High
7/27/2017Needham & Company LLCReiterated RatingHoldHigh
7/26/2017BMO Capital MarketsReiterated RatingOutperform$240.00 ➝ $260.00High
7/26/2017Stifel NicolausUpgradeHold ➝ Buy$160.00 ➝ $300.00High
7/11/2017HC WainwrightInitiated CoverageBuy ➝ Buy$300.00High
5/15/2017BMO Capital MarketsReiterated RatingBuy$240.00Low
5/5/2017BMO Capital MarketsReiterated RatingBuy$240.00High
3/10/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$120.00 ➝ $200.00High
3/9/2017Stifel NicolausBoost Price TargetHold$100.00 ➝ $140.00Low
11/4/2016BMO Capital MarketsReiterated RatingHold$120.00N/A
11/4/2016WedbushReiterated RatingNeutral$80.00N/A
8/5/2016WedbushReiterated RatingNeutral$80.00N/A
(Data available from 8/2/2016 forward)
Tetraphase Pharmaceuticals logo
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $2.20
Low: $2.18
High: $2.27

50 Day Range

MA: $2.20
Low: $2.20
High: $2.20

52 Week Range

Now: $2.20
Low: $0.56
High: $8.60


282,689 shs

Average Volume

932,542 shs

Market Capitalization

$15.98 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Tetraphase Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Tetraphase Pharmaceuticals in the last year:
View the latest analyst ratings for TTPH.

What is the current price target for Tetraphase Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Tetraphase Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Tetraphase Pharmaceuticals in the next year.
View the latest price targets for TTPH.

What is the current consensus analyst rating for Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TTPH.

What other companies compete with Tetraphase Pharmaceuticals?

How do I contact Tetraphase Pharmaceuticals' investor relations team?

Tetraphase Pharmaceuticals' physical mailing address is 480 ARSENAL WAY, WATERTOWN MA, 02472. The biopharmaceutical company's listed phone number is 617-715-3600 and its investor relations email address is [email protected] The official website for Tetraphase Pharmaceuticals is